SCHEMBL24547634

SCHEMBL24547634

Cn1ncc2c1c1ccccc1n2C(=O)C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 4/20 0.38
HTT P42858 3/20 0.38
HSD17B10 Q99714 3/20 0.38
SSTR4 P31391 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SSTR1 P30872 1/20 0.38
SSTR2 P30874 1/20 0.38
SSTR3 P32745 1/20 0.38
SSTR5 P35346 1/20 0.38
KMT2A Q03164 3/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
TFPI2 P48307 1/20 0.37
MAPK1 P28482 1/20 0.37
FASN P49327 2/20 0.36
PKM P14618 1/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24547758 0.83 ELANE (0.46) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547660 0.82 ELANE (0.45) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547757 0.82 ELANE (0.45) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547762 0.81 HSD17B10 (0.41) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547633 0.79 RIPK1 (0.38) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL27112816 0.74 HPGD (0.36) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547744 0.73 KDM4E (0.45) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547766 0.72 KDM4E (0.45) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL24547742 0.71 P2RX4 (0.56) KDM4EALDH1A1HPGDHTTHSD17B10
SCHEMBL30262679 0.70 PIM1 (0.40) LMNAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
WO-2022126179-A1 OXYTOCIN RECEPTOR MODULATORS THE UNIVERSITY OF SYDNEY (AU) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS OXTR, AVPR1B, AVPR1A KDM4E 4374/4885ALDH1A1 3129/4885HPGD 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.